210 results
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
12 Mar 20
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-year 2019 Financial Results and Provides a Business Update
7:04am
and Pipeline Highlights
XERMELO® (telotristat ethyl)
XERMELO U.S. net sales were $31.0 million in 2019.
In December, Lexicon completed a safety review … of the initial safety run-in cohort of The Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, a Phase 2a clinical study
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
31 Jul 23
Lexicon Elects Diane E. Sullivan to Board of Directors
4:02pm
with:
heart failure or
type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors
IMPORTANT SAFETY INFORMATION
Dosing: Assess … . The safety profile of INPEFA across eGFR subgroups in these studies was consistent with the known safety profile. There was an increase in volume-related
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
2 May 24
Lexicon Pharmaceuticals Reports First Quarter 2024
4:07pm
risk factors
IMPORTANT SAFETY INFORMATION
Dosing: Assess renal function and volume status and, if necessary, correct volume depletion prior … to 60 mL/min/1.73 m2) and in patients with heart failure with eGFR < 60 mL/min/1.73 m2. The safety profile of INPEFA across eGFR subgroups
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
29 Jul 19
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquistatm (Sotagliflozin) Type 2 Diabetes Phase 3 Program
12:00am
the efficacy and safety of Zynquista in adults with type 2 diabetes on various therapeutic backgrounds (i.e., diet and exercise alone, metformin … and SOTA-CKD4 are the first trials to report data from the program:
SOTA-MET is evaluating the efficacy and safety of Zynquista (400 mg once daily
8-K
EX-99.1
nd46xn4ppxn9savg7w
3 Aug 23
Lexicon Pharmaceuticals Reports Second Quarter 2023
4:08pm
8-K
EX-99.1
srvq0
28 Jul 09
Reports 2009 Second Quarter Financial Results
12:00am
8-K
EX-99.1
x319s
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
8-K
EX-99.1
wbezs1eexjnanmligt
8 Nov 23
Lexicon Pharmaceuticals Reports Third Quarter 2023
7:22am
8-K
EX-99.1
mkox75 jpmcg
27 Oct 09
Lexicon Pharmaceuticals Provides Clinical Pipeline Update
12:00am
8-K
EX-99.1
0n0 3dfwk
1 Nov 11
Lexicon Pharmaceuticals Reports on Clinical Program Status
12:00am
8-K
EX-99.1
fjc y80yp
1 Aug 06
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
gm366wo8dulw sg8c
22 Feb 12
Reports 2011 Fourth Quarter and Full Year Financial Results
12:00am
8-K
EX-99.3
ov60labe
20 Nov 14
Lexicon Announces Proposed Common Stock Offering
12:00am